易明医药(002826) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 154,617,632.87, an increase of 31.21% year-on-year[8] - Net profit attributable to shareholders was CNY 3,902,919.95, reflecting a growth of 6.14% compared to the same period last year[8] - Total operating revenue for Q3 2020 reached ¥154,617,632.87, compared to ¥117,837,821.12 in the previous period, indicating a growth of approximately 31.2%[46] - Net profit for Q3 2020 was ¥3,902,919.95, compared to ¥3,676,971.21 in the same period last year, showing a growth of approximately 6.1%[48] - The net profit for the current period is 17,092,345.30, an increase from 15,611,341.88 in the previous period, indicating a growth of approximately 9.5%[56] - The net profit for the current period was a loss of ¥10,264,586.90, compared to a profit of ¥1,722,769.45 in the previous period, indicating a significant decline[60] Cash Flow - Net cash flow from operating activities increased significantly by 232.24% to CNY 34,066,511.43[8] - The net cash flow from operating activities was ¥42,129,411.90, a recovery from a negative cash flow of ¥4,667,121.46 in the previous period[62] - The net cash flow from operating activities for the period was ¥84,467,087.03, a significant improvement compared to the previous period's net cash flow of -¥132,224,979.79[64] - Total cash inflow from operating activities reached ¥624,704,539.11, up from ¥423,194,485.13 in the previous period, indicating a growth of approximately 47.5%[64] Assets and Liabilities - Total assets at the end of the reporting period were CNY 833,478,346.72, a decrease of 0.23% compared to the end of the previous year[8] - The company's current assets decreased to ¥376,725,288.34 from ¥400,567,707.61, reflecting a decline of approximately 5.9%[37] - The total liabilities decreased to ¥168,929,188.93 from ¥183,236,800.46, representing a decline of about 7.8%[39] - Total liabilities decreased to ¥79,004,402.72 in Q3 2020 from ¥131,400,049.49 in the previous period, a reduction of approximately 40%[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,674[12] - The largest shareholder, Gao Fan, holds 26.46% of the shares, with 50,744,682 shares pledged[12] Expenses and Costs - Total operating costs for Q3 2020 were ¥148,717,393.09, up from ¥114,170,579.44 in the previous period, reflecting an increase of about 30.2%[47] - The company's financial expenses decreased by ¥8.99 million year-on-year, a reduction of 56.74%, primarily due to a decrease in total loan amounts and corresponding interest payments[11] - Research and development expenses for Q3 2020 were ¥1,194,360.82, compared to ¥932,100.92 in the previous period, reflecting an increase of approximately 28.2%[47] Government Support - The company received government subsidies amounting to CNY 3,951,051.58, primarily from local support policies[9] - The company’s other income rose by ¥57.08 million, an increase of 32.43%, due to government subsidies received for meeting economic contribution standards[12] Investment Activities - The company reported a net investment cash flow of -¥169.01 million, a decrease of 90.35% compared to the previous year, primarily due to reduced cash outflows for short-term financial products[17] - The company reported a total investment cash outflow of ¥87,221,470.60, compared to ¥501,186,552.32 in the previous period, indicating a reduction in investment activities[63] Earnings Per Share - The basic earnings per share remained at CNY 0.02, unchanged from the previous period[8] - The company reported a basic and diluted earnings per share of -0.03, compared to 0.01 in the previous period[53] - Basic and diluted earnings per share for the current period are both 0.09, compared to 0.08 in the previous period, reflecting a slight increase[57] Other Financial Metrics - The weighted average return on net assets was 0.59%, showing no change from the previous period[8] - The company reported no significant changes in its non-recurring gains and losses during the reporting period[10] - The company has no reported non-operating fund occupation by controlling shareholders or related parties during the reporting period[31] - There were no violations regarding external guarantees during the reporting period[30]